Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines.
Fatima LaherZoe MoodieKristen W CohenNicole A GrunenbergLinda-Gail BekkerMary A AllenNicole FrahmNicole L YatesLynn MorrisMookho MalahlehaKathryn Therese MngadiBrodie DanielsCraig InnesKevin SaundersShannon GrantChenchen YuPeter B GilbertSanjay PhogatCarlos A DiazGranadosMarguerite KoutsoukosOlivier Van Der MeerenCarter BentleyNonhlanhla N MkhizeMichael N PensieroVijay L MehraJames G KublinLawrence CoreyDavid C MontefioriGlenda Elisabeth GrayM Juliana McElrathGeorgia D TomarasPublished in: PLoS medicine (2020)
ClinicalTrials.gov NCT02404311. South African National Clinical Trials Registry (SANCTR number: DOH--27-0215-4796).
Keyphrases
- hiv positive
- hiv infected
- antiretroviral therapy
- south africa
- clinical trial
- double blind
- hiv testing
- men who have sex with men
- human immunodeficiency virus
- immune response
- hepatitis c virus
- hiv aids
- placebo controlled
- study protocol
- phase ii
- quality improvement
- randomized controlled trial
- phase iii
- toll like receptor
- inflammatory response